After evaluating YTHDF1’s role in advancing tumor cell cycle progression, we examined its known targets, CDK2 and CDK4, in non-small cell lung cancer using RNA Binding Protein Immunoprecipitation Assay (RIP) [23]. Here, CDK4 is linked to non-small cell lung carcinoma.